Healthcare · Biotechnology
Price
$17.67
Market Cap
$1.6B
Employees
143
Beta
0.90
Avg Volume
2,913,703
CEO
Stephen F. Mahoney
Business Description
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Business History
Price Overview
Last updated: Jun 27, 2026 10:08am (just now)$17.90
+0.51 (+2.93%)
Day Range
$17.38 – $18.38
52-Week Range
$13.18 – $34.29
50-Day MA
$16.13
200-Day MA
$24.11
Volume
3,789,507.00
Analyst Price Targets
Low
$26.00
Consensus
$36.86
High
$50.00
(36 analysts)
Share Structure
Outstanding
89,997,461.00
Float
73,781,494.00
Free Float
82.0%
High free float
— 82.0% of shares trade freely, ~18% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-5.32
Stock Price: $17.67
EPS (Diluted): -3.32
EPS (Diluted): -3.32
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
3.65
Stock Price: $17.67
Total Equity: $722.17M
Shares: 84,803,355
Total Equity: $722.17M
Shares: 84,803,355
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-4.25
Market Cap: $1.59B
Total Debt: $49.94M
Cash: $212.38M
EBITDA: -$337.19M
Total Debt: $49.94M
Cash: $212.38M
EBITDA: -$337.19M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$2.5B
Market Cap: $1.59B
Total Debt: $49.94M
Cash: $212.38M
Total Debt: $49.94M
Cash: $212.38M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
37.25
Stock Price: $17.67
Revenue: $70.85M
Shares: 84,803,355
Revenue: $70.85M
Shares: 84,803,355
EV/Sales (Total value vs revenue — works when P/E can't)
API34.97
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
100.0%
Gross Profit: $70.85M
Revenue: $70.85M
Revenue: $70.85M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-512.9%
Operating Income: -$363.40M
Revenue: $70.85M
Revenue: $70.85M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-483.6%
Net Income: -$342.60M
Revenue: $70.85M
Revenue: $70.85M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-60.7%
Net Income: -$342.60M
Total Equity: $722.17M
Total Equity: $722.17M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-52.3%
Operating Income: -$363.40M
Tax Rate: 0.0%
Equity: $722.17M
Total Debt: $49.94M
Cash: $212.38M
Tax Rate: 0.0%
Equity: $722.17M
Total Debt: $49.94M
Cash: $212.38M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
12.65
Current Assets: $894.23M
Current Liabilities: $70.70M
Current Liabilities: $70.70M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.07
Short-Term Debt: $0.00
Long-Term Debt: $49.94M
Total Debt: $49.94M
Total Equity: $722.17M
Long-Term Debt: $49.94M
Total Debt: $49.94M
Total Equity: $722.17M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.84
Revenue: $70.85M
Shares: 84,803,355
Shares: 84,803,355
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$8.52
Total Equity: $722.17M
Shares: 84,803,355
Shares: 84,803,355
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-3.27
Operating CF: -$276.39M
CapEx: -$495,000
Shares: 84,803,355
CapEx: -$495,000
Shares: 84,803,355
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $17.67
Stock Price: $17.67
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$342.60M
Net Income: -$342.60M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares VRDN against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 22, 2026 3:55am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.0M | $1.8M | $314,000 | $302,000 | $70.8M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $3.0M | $1.8M | $314,000 | $302,000 | $70.8M |
| Operating Expenses | $82.7M | $136.1M | $254.8M | $299.3M | $434.2M |
| Operating Income | -$79.7M | -$134.3M | -$254.5M | -$299.0M | -$363.4M |
| Net Income | -$79.4M | -$129.9M | -$237.7M | -$269.9M | -$342.6M |
| EBITDA | -$79.3M | -$129.1M | -$235.4M | -$265.7M | -$337.2M |
| EPS | $-6.66 | $-3.91 | $-5.31 | $-3.98 | $-3.32 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 22, 2026 3:55am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $42.3M | $155.6M | $102.8M | $99.6M | $212.4M |
| Total Current Assets | $200.2M | $424.6M | $486.5M | $738.5M | $894.2M |
| Total Assets | $203.7M | $435.1M | $490.4M | $742.4M | $899.4M |
| Current Liabilities | $13.6M | $33.3M | $26.6M | $47.9M | $70.7M |
| Long-Term Debt | $0 | $4.6M | $20.2M | $20.6M | $49.9M |
| Total Liabilities | $16.0M | $40.0M | $48.4M | $70.8M | $177.3M |
| Total Equity | $187.7M | $395.1M | $442.0M | $671.6M | $722.2M |
| Retained Earnings | -$358.3M | -$488.2M | -$725.9M | -$995.9M | -$1.3B |
Cash Flow (Annual)
Last updated: Jun 22, 2026 3:55am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$54.6M | -$93.8M | -$184.2M | -$232.3M | -$276.4M |
| Capital Expenditure | $-338,000 | $-797,000 | $-898,000 | $-511,000 | $-495,000 |
| Free Cash Flow | -$54.9M | -$94.6M | -$185.1M | -$232.8M | -$276.9M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$3.6M | $113.3M | -$52.8M | -$3.2M | $112.8M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 3:35pm (18h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$244.4M $200.2M – $326.9M
|
$579.9M $579.9M – $579.9M
|
$856.6M $560.3M – $1.3B
|
$1.1B $736.8M – $1.7B
|
| EBITDA |
-$244.4M -$326.9M – -$200.2M
|
-$579.9M -$579.9M – -$579.9M
|
-$856.6M -$1.3B – -$560.3M
|
-$1.1B -$1.7B – -$736.8M
|
| Net Income |
-$214.6M -$270.4M – -$158.9M
|
-$15.9M -$262.1M – $181.1M
|
$137.0M $75.4M – $221.3M
|
$257.8M $141.9M – $416.5M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 22, 2026 3:55am (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -40.2% | -82.3% | -3.8% | +23,359.9% |
| Gross Profit Growth | -40.2% | -82.3% | -3.8% | +23,359.9% |
| Operating Income Growth | -68.5% | -89.5% | -17.5% | -21.5% |
| Net Income Growth | -63.5% | -83.0% | -13.6% | -26.9% |
| EBITDA Growth | -62.9% | -82.3% | -12.9% | -26.9% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 9:04am (1h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-11 | Fairmount Funds Management LLC | P-Purchase | 1,176,470.00 | $17.00 | $20.0M |
| 2026-03-03 | Harmon Seth | F-InKind | 2,031.00 | $30.19 | $61,316 |
| 2026-03-03 | Beetham Thomas W. | F-InKind | 3,048.00 | $30.19 | $92,019 |
| 2026-03-03 | Tousignant Jennifer | F-InKind | 1,675.00 | $30.19 | $50,568 |
| 2026-03-03 | Mahoney Stephen F. | F-InKind | 7,408.00 | $30.19 | $223,648 |
| 2026-03-02 | Tousignant Jennifer | A-Award | 119,300.00 | $30.25 | $3.6M |
| 2026-03-02 | Tousignant Jennifer | A-Award | 23,850.00 | $0.00 | $0 |
| 2026-03-03 | Tousignant Jennifer | M-Exempt | 5,169.00 | $0.00 | $0 |
| 2026-03-03 | Tousignant Jennifer | M-Exempt | 5,169.00 | $0.00 | $0 |
| 2026-03-03 | Tousignant Jennifer | F-InKind | 1,724.00 | $29.32 | $50,548 |
| 2026-03-02 | Harmon Seth | A-Award | 102,850.00 | $30.25 | $3.1M |
| 2026-03-02 | Harmon Seth | A-Award | 20,550.00 | $0.00 | $0 |
| 2026-03-03 | Harmon Seth | M-Exempt | 6,267.00 | $0.00 | $0 |
| 2026-03-03 | Harmon Seth | M-Exempt | 6,267.00 | $0.00 | $0 |
| 2026-03-03 | Harmon Seth | F-InKind | 2,091.00 | $29.32 | $61,308 |
| 2025-03-03 | Harmon Seth | 0.00 | $0.00 | $0 | |
| 2025-03-03 | Tousignant Jennifer | 0.00 | $0.00 | $0 | |
| 2026-03-02 | Beetham Thomas W. | A-Award | 176,550.00 | $30.25 | $5.3M |
| 2026-03-02 | Beetham Thomas W. | A-Award | 35,300.00 | $0.00 | $0 |
| 2026-03-03 | Beetham Thomas W. | M-Exempt | 9,409.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for VRDN — it's generated by the pipeline (
market-narrative step).
No community reviews yet for VRDN.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30